Destruction of bone is often a consequence of the development of a primary benign or malignant tumour or tumourlike lesion in bone. This results in considerable morbidity, including bone pain and pathological fracture. Although the osteolysis associated with the enlargement of primary mesenchymal tumours and tumour-like lesions of bone is thought to be carried out by osteoclasts, the precise cellular and humoral mechanisms which contribute are unknown.
Destruction of bone is often a consequence of the development of a primary benign or malignant tumour or tumourlike lesion in bone. This results in considerable morbidity, including bone pain and pathological fracture. Although the osteolysis associated with the enlargement of primary mesenchymal tumours and tumour-like lesions of bone is thought to be carried out by osteoclasts, the precise cellular and humoral mechanisms which contribute are unknown. 1, 2 Osteoclasts are specialised, multinucleated, bone-resorbing cells which form part of the mononuclear phagocyte system. 3 They are formed by the fusion of circulating mononuclear precursor cells of haematopoietic origin. Studies in vitro have defined the ontogeny of the osteoclast and characterised the essential cellular and humoral factors which are required for its differentiation from haematopoietic and circulating osteoclast precursors. In both the mouse and man, mononuclear osteoclast precursors circulate in the monocyte fraction and express a monocyte/macrophage rather than a mature osteoclast phenotype. [4] [5] [6] These circulating precursors express the receptor activator for nuclear factor B (RANK) and their differentiation into osteoclasts requires the presence of macrophage-colony stimulating factor (M-CSF) and involves a receptor-ligand interaction with osteoblasts/bone stromal cells which express the membrane-bound ligand for RANK (RANKL). 7, 8 In previous studies, we have shown that tumour-associated macrophages (TAMs) isolated from primary human breast and mouse mammary carcinomas, when co-cultured with bone-derived stromal cells in the presence of 1,25 dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) and M-CSF, are able to differentiate into multinucleated osteoclasts which can carry out extensive resorption of lacunar bone. 9, 10 This finding is of interest with regard to the pathogenesis of tumour osteolysis since, in addition to an increase in osteoclast numbers, a prominent macrophage infiltrate is commonly found in primary and metastatic tumours of bone. [11] [12] [13] Osteoclasts are also required for the growth of metastatic and primary mesenchymal tumours of bone and osteolysis involves recruitment of osteoclast precursors and the activation of mature osteoclasts.
1,2
The cellular and humoral mechanisms accounting for the formation and activation of osteoclasts which cause the osteolysis that accompanies the enlargement of mesenchymal tumours in bone are unknown.
14 Our aim was to analyse the cellular mechanisms which contribute to the formation of osteoclasts in benign and malignant mesenchymal tumours.
In particular, we sought to determine whether tumourassociated macrophages in these neoplasms are capable of differentiation into osteoclasts, and to characterise the cellular and humoral conditions required for this to occur.
Materials and Methods
Incubations were performed in alpha minimal essential medium (MEM) supplemented with L-glutamine (2 mM), benzylpenicillin (100 IU/ml), streptomycin (100 g/ml), and 10% fetal calf serum (FCS) (Gibco, Paisley, UK). Cloned, hormone-responsive, calcitonin-receptor-negative, osteoblast-like UMR 106 cells derived from a rat osteosarcoma-derived cell line were obtained from Professor T. J. Martin (Melbourne, Australia). 15 (1)) and from the extraskeletal component of a single primary bone tumour (malignant fibrous histiocytoma) which showed extensive soft-tissue infiltration. The tumour tissue was cut into small pieces (1 ϫ 1 ϫ 1 mm), placed in sterile containers filled with 10 ml of MEM containing 1mg/ml of collagenase type I (Sigma-Aldrich), and the mixture gently agitated by a magnetic stirrer for one hour at 37°C. 16 This was followed by incubation for a further 30 minutes in 0.05% trypsin. The digested tissue was filtered with a 70 m cell strainer (Falcon, c/o Fahrenheit, Milton Keynes, UK) and the filtrate then centrifuged at 800 g for ten minutes. The cell pellet was finally resuspended in 10 ml of MEM with 10% added FCS (MEM/FCS). The number of macrophages was counted in a haemocytometer after lysis of red blood cells using a 5% (v/v) solution of acetic acid. M dexamethasone. In all cultures, the medium (with added factors) was replaced entirely every three days. In addition, cultures of isolated TAMs from all tumours were cultured in the absence of UMR 106 cells with soluble RANKL (30 ng/ ml), M-CSF (25 ng/ml) and dexamethasone (10 -8 M) for up to 14 days. Cultures on coverslips were set up in duplicate and on the dentine slices in triplicate.
Evidence of histochemical/immunophenotypic and functional evidence of macrophage/osteoclast differentiation by cells cultured on the glass coverslips and dentine slices were assessed after incubation of the cell cultures for 24 hours and 7 and 14 days. Identification of macrophage and osteoclast cytochemical markers in isolated and cultured cells. After incubation for 24 hours and 7 and 14 days, the cultures on the glass coverslips were fixed and stained cytochemically for the osteoclast-associated enzyme tartrate-resistant acid phosphatase (TRAP), 17 and immunocytochemically with the monoclonal antibody 23C6 18 for the presence of the vitronectin receptor (VNR), an osteoclast-specific antigen, using an indirect immunoperoxidase technique. 19 In addition, these cultures were immunocytochemically stained with the monoclonal antibody GRS1 for the presence of the macrophage-associated antigen CD14 which is known not to be expressed by osteoclasts.
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Functional characterisation of isolated and cultured cells. Cell cultures on the slices of dentine were incubated for 24 hours and 7 and 14 days. At the end of the incubation period, the slices were removed, placed in NH 4 OH (0.1M) for two hours and then ultrasonicated to remove adherent cells. They were then washed with distilled water and stained with 0.5% (v/v) Toluidine Blue for three minutes, washed again and then air-dried. The extent of lacunar resorption was quantified by counting the number of resorption pits on the dentine slice on light microscopy using image-analysis software. Isolation of CD14-positive and CD14-negative cells from mesenchymal tumours. In order to confirm the macrophagic nature of the mononuclear cells undergoing osteoclast differentiation, we isolated mononuclear cells on the basis of expression of the macrophage marker CD14. Tumour tissue was washed in MEM then dissected into small fragments and incubated with collagenase type 1 (1 mg/ml) for 45 minutes. After further incubation for 45 minutes with 1:5000 Versene (Life Technology, Paisley, UK), the suspension was filtered and centrifuged as described above. The cell pellet was resuspended in 1 ml of MEM/FCS and then passed through a mini MACS filter (Milteny Biotec Ltd, Woking, UK) in which the cell suspension added to the column was incubated with mini MACS CD14 beads (Milteny Biotec) at 4°C for 20 minutes. The cell suspension was passed through a magnetic column whereby the CD14-positive beads were retained under the magnetic field while CD14-negative cells were washed and collected in a sterile container. After removing the column from the magnetic field, the CD14-positive cells collected in the column were washed using mini MACS buffer. Sorted cells from both selections were then washed twice in MEM/FCS, counted and then cultured for 14 days in the presence of soluble RANKL-positive, M-CSF and dexamethasone as described above for up to 14 days.
Results
Characterisation of TAMs isolated from mesenchymal tumours. After incubation for 24 hours on glass coverslips the cells isolated from all seven tumours, when cultured in the presence or absence of UMR 106 cells, 1,25 (OH) 2 D 3 and M-CSF, were found to be entirely negative for the osteoclast markers TRAP and VNR. 17, 18 They strongly expressed CD14, a macrophage antigen which is known not to be present on osteoclasts. 20 The mononuclear cells isolated from the tumours thus expressed only the phenotypic characteristics of macrophages and not osteoclasts. The 24-hour cultures of cells on dentine slices again both in the presence and absence of UMR 106 cells, 1,25(OH) 2 D 3 and M-CSF, showed no evidence of resorption of lacunar bone. The CD14-positive and CD14-negative mononuclear cell populations isolated from all tumours showed no evidence of bone resorption after incubation for 24 hours on dentine slices. The 24-hour cultures of UMR 106 cells alone showed no expression of TRAP or VNR. TAM-osteoclast differentiation. In the presence of 1,25 (OH) 2 D 3 , M-CSF and dexamethasone, numerous multinucleated cells, expressing the osteoclast-associated markers, TRAP and VNR, were found to be present in all 14-day TAM-UMR 106 co-cultures incubated on glass coverslips (Fig. 1) . Mononuclear and multinucleated cells positive for CD14 were also noted in these cultures. In UMR 106-TAM co-cultures, no expression of TRAP or VNR was seen when either UMR 106 cells, 1,25(OH) 2 D 3 or M-CSF was omitted.
After incubation for 14 days, VNR-and TRAP-positive multinucleated cells were also formed on glass coverslips when TAMs from all tumours were cultured in the absence of UMR 106 cells but in the presence of RANKL, M-CSF and dexamethasone. VNR-and TRAP-positive multinucleated cells were not seen in 14-day cultures of TAMs alone incubated in the absence of either soluble RANKL or M-CSF. Mononuclear cells positive for CD14 were also found in these 14-day cultures.
Co-cultures of UMR 106 cells and TAMs isolated from all tumours, incubated on slices of dentine for 14 days in the presence of 1,25(OH) 2 D 3 , M-CSF and dexamethasone, showed functional evidence of the differentiation of osteoclasts with the formation of numerous areas of lacunar resorption on all slices. In addition, cultures of TAMs isolated from all tumours, which were incubated alone in the presence of soluble RANKL, M-CSF and dexamethasone, also resulted in lacunar resorption on dentine slices (Fig. 2) which was evident as areas of osteolysis composed of single resorption pits or multiple compound areas of lacunar excavation on the surface of each slice. The extent of the mean percentage area of lacunar resorption on the slices on which TAMs had been co-cultured with UMR-106 cells varied depending on the type of tumour (range 0.1% to 2.3%). The mean percentage areas of lacunar resorption for the two cases of liposarcoma and the single cases of malignant fibrous histiocytoma, malignant schwannoma, lipoma and schwannoma were 0.1%, 0.93%, 1.93%, 0.1% and 0.55%, respectively. In the absence of soluble RANKL or M-CSF, lacunar resorption was not seen on dentine slices in 14-day TAM cultures. Similarly, when either UMR 106 cells, M-CSF or 1,25(OH) 2 D 3 was omitted from co-cultures on dentine slices, lacunar resorption was not found. Evidence of osteoclast differentiation by CD14-positive cells. In order to confirm the macrophagic nature of the mononuclear precursor cells from which osteoclasts formed, we further characterised these cells in terms of their expression of the monocyte/macrophage antigen CD14. We found that 14-day cultures on glass coverslips of the CD14-positive population of mononuclear cells isolated from all tumours, when incubated in the presence of RANKL, M-CSF and dexamethasone, showed the formation of numerous TRAP-and VNR-positive mononuclear and multinucleated cells. The 14-day cultures of the CD14-positive cells on dentine slices also showed evidence of extensive lacunar resorption with up to 8.52% of the surface area of each slice being resorbed. By contrast, 14-day cultures of the CD14-negative mononuclear cell population on glass coverslips and dentine slices showed no evidence of the formation of osteoclasts as measured by the expression of TRAP or VNR or the formation of resorption pits.
Discussion
Our study has shown that benign and malignant mesenchymal tumours contain mononuclear cells which are capable of differentiation into mature functional osteoclasts. Our analysis has shown that these osteoclast precursors are present in the CD14-positive TAM population of mononuclear cells isolated from mesenchymal tumours. We also found that, like monocytes and other tissue macrophages, 5, 6 these cells differentiate into mature osteoclasts in the presence of RANKL-expressing osteoblastic cells and M-CSF. Since osteoclasts are known to be required for the osteolysis associated with the enlargement of primary tumours and tumour-like lesions of bone, 1,12 differentiation of TAM-osteoclasts is likely to be an important cellular mechanism whereby this osteolysis is carried out. TAMs are derived from circulating blood monocytes. 13, 21 Mesenchymal stromal cells as well as tumour cells have been shown to secrete chemoattractant factors for monocytes 22, 23 and TAMs are known to form a significant cellular component of mesenchymal tumours. 24, 25 The extent of the TAM infiltrate in different types of benign and malignant tumour is highly variable; this could account for some of the variations seen in the extent of the formation of osteoclasts and lacunar resorption noted between the different tumours analysed in our study. Although previous studies have shown that monocytes, 26 macrophages, 27 and their fused products macrophage polykaryons, 28 as well as tumour cells themselves, 29 are capable of degrading both the mineral and organic components of bone, there is no evidence to indicate that these cells are independently capable of resorption of lacunar bone. It has been shown, however, in both the mouse and man that TAMs and not tumour cells isolated from carcinomas are capable of differentiation into lacunar bone-resorbing cells. 9, 10 Mononuclear osteoclast precursor cells are known to be present in the macrophage infiltrate of inflammatory and neoplastic lesions; 10,30 these precursors are derived from blood monocytes, which are known to be attracted to constituents of the bone matrix. 31 Our results show that mononuclear osteoclast precursors can be found in the macrophage fraction of mesenchymal tumours and that these cells express the phenotypic characteristics of macrophages and not osteoclasts. The latter are known to have a highly specific cytochemical, antigenic and ultrastructural phenotype and, in contrast to monocytes, macrophages and macrophage polykaryons, are uniquely capable of resorption of lacunar bone. 3 Osteoclast precursors have been shown to lose and acquire macrophage and osteoclast markers respectively in the process of the differentiation of osteoclasts. 31, 32 The cellular and humoral elements which we have identified as being essential for TAM-osteoclast differentiation can be found in the microenvironment of a bone tumour or tumour-like lesion. TAM-osteoclast differentiation may therefore represent a means whereby the osteolysis which accompanies tumour growth in bone is achieved. Clohisy et al 1, 2 have shown that osteoclasts are entirely responsible for the osteolysis which accompanies the enlargement of epithelial and mesenchymal tumours in bone. They have also shown that osteolytic tumours promote the formation, survival and activity of osteoclasts. The number of TAMs which differentiate into osteoclasts may thus function as a determining factor in defining the extent of osteolysis associated with an interosseous mesenchymal lesion. This accords with the observation that many benign and malignant osteolytic tumours of bone, such as non-ossifying fibroma, malignant fibrous histiocytoma and giant-cell tumour of bone, are characterised morphologically by the presence of numerous macrophages. Differences in the extent of lacunar resorption which we noted in the individual lesions examined in our study could be due to differences in the extent of the macrophage infiltrate in these different tumour samples. The secretion of macrophage chemotactic factors and the stimulation of the differentiation and activation of osteoclasts by cytokines and growth factors produced by mesenchymal tumour cells are also likely to play a role in determining the extent of tumour osteolysis associated with mesenchymal tumours of bone. Secreted products of breast cancer cells have been shown to increase the formation of mononuclear phagocyte-osteoclasts. 36 Our results also suggest that the osteolysis associated with mesenchymal tumours may be prevented by agents which inhibit the formation of osteoclasts and bone resorption, such as osteoprotegerin and bisphosphonates.
